Stoke Therapeutics Stock: Dravet Data Sends Shares Soaring One For Watchlist (NASDAQ:STOK)
tadamichi Investment Overview Stoke Therapeutics’ (NASDAQ:STOK) stock has been soaring in response to the positive data the company shared from two open-label Phase 1/2a studies and two open-label extension (“OLE”) studies of its lead drug candidate STK-001 in children and adolescents ages 2 to 18 with Dravet syndrome, on March 25th this year. Stoke, which…